Concept Companies, a national commercial real estate developer with a specialty across multiple asset classes including science and technology, and Lacerta Therapeutics, Inc., a leader in the AAV gene therapy space, today announced a strategic collaboration providing Lacerta with access to financing to support expansion of operations and new facilities. The financing is being provided via Agility Venture Capital, the funding arm of Concept Companies.
The two companies also announced the groundbreaking for Lacerta’s new 11,961-square-foot state-of-the-art cGMP manufacturing facility located in Alachua’s Progress District, adjacent to its current site in Copeland Park, which the company has occupied since 2020. Lacerta expects the creation of an additional 20 full-time jobs to support clinical manufacturing of their lead AAV gene therapy products.
“The funding vehicle via Agility is indicative of the exceptional relationship between Concept Companies and Lacerta, and our strong commitment to the region,” said Dr. Edgar Rodriguez-Lebron, President & CEO of Lacerta Therapeutics. “It also reflects the growth and success of Lacerta and the Alachua biotech hub. We are excited to join forces with Concept as we continue our mission to bring these much-needed, novel medicines to the clinic.”Learn more about Concept Companies and Lacerta Therapeutics Form a Strategic Partnership Around Facilities Expansion and Financing